Conference Correspondent

Conference Correspondent — May 28, 2020
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.
Read Article

Conference Correspondent — May 28, 2020
Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer.
Read Article

Conference Correspondent — May 28, 2020
Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma.
Read Article

Conference Correspondent — March 20, 2020
Insights about real-world clinical experience with new drugs, such as acalabrutinib, are highly valuable. At ASH 2019, researchers evaluated acalabrutinib use in real-world patients with mantle-cell lymphoma and chronic lymphocytic leukemia.
Read Article

Conference Correspondent — March 20, 2020
Current treatments for chronic lymphocytic leukemia are limited by cost, toxicity, and duration of response. In the future, less toxic first-line chemotherapy-free regimens administered for a fixed duration of time may improve outcomes.
Read Article

Conference Correspondent — March 20, 2020
Primary analysis results of a phase 1b/2 trial showed obinutuzumab + polatuzumab vedotin + lenalidomide was associated with high complete response rates and a favorable safety profile in heavily pretreated and refractory patients with follicular lymphoma.
Read Article

Conference Correspondent — March 20, 2020
Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Read Article

Conference Correspondent — March 20, 2020
Diffuse large B-cell lymphoma is an aggressive type of non-Hodgkin lymphoma that is particularly difficult to treat if the patient becomes refractory to or relapses after initial treatment. Chances of survival are especially poor for people who are not eligible for stem-cell transplant.
Read Article

Conference Correspondent — January 16, 2020
Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses.
Read Article

Conference Correspondent — January 16, 2020
Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions.
Read Article

Page 10 of 44